Table 1.
Participant baseline characteristics at enrolment for a total number of participants (n = 122; interquartile range [IQR]; standard deviation [SD]).
| Total number of participants (n) | 122 |
|---|---|
| Age, years, median (IQR) | 36 (32–44) |
| Gender; men, n (%) | 98 (80) |
| Staging | |
| Tumor severity T0 (ACTG), n (%) | 18 (15) |
| Karnofsky performance status ≤ 70%, n (%) | 43 (35) |
| Illness severity S1, n (%) | 67 (55) |
| Symptoms | |
| Edema present, n (%) | 60 (51) |
| Visceral disease present, n (%) | 8 (7) |
| Oral involvement present, n (%) | 41 (35) |
| HIV Characteristics | |
| Knew HIV+ diagnosis prior to KS diagnosis, n (%) | 64 (53) |
| Months HIV+ diagnosis known, median (IQR) (n=61) | 16 (6–57) |
| On ART prior to KS diagnosis, n (%) | 61 (50) |
| Months on ART prior to diagnosis, median (IQR) (n=61) | 16 (6–57) |
| CD4 count, median (IQR) (n=115) | 197 (96–337) |
| HIV viral load log copies/ml/median (IQR) (n=116) | 3 (2–5) |
| HIV viral load suppressed < 1000 copies/ml, n (%) (n=116) | 67 (58) |
| Baseline Lab Results | |
| Hemoglobin, g/dl/mean (SD) | 11 (3) |
| Platelets, 103/µl/median (IQR) | 234 (157–313) |
| White blood cell, 103/µl/median (IQR) | 5 (4–6) |
| Absolute neutrophil count, 103/µl/ median (IQR) | 2 (1–3) |
| Creatinine, mg/dl/median (IQR) | 0.8 (0.7–0.9) |
| Bilirubin, mg/d/ median (IQR) (n=111) | 0.4 (0.3–0.5) |